Biological and Clinical Assessment of a New Bisphosphonate, (Chloro-4 Phenyl) Thiomethylene Bisphosphonate, in the Treatment of Paget's Disease of Bone
Biological and Clinical Assessment of a New Bisphosphonate, (Chloro-4 Phenyl) Thiomethylene Bisphosphonate, in the Treatment of Paget's Disease of Bone.pdf
[en] Several Biophosphonates have been used as therapeutic agents for Paget's bone disease. (Chloro-4 phenyl)thiomethylene-bisphosphonate (CIPsMBP) has recently been shown to have significant antiosteoclastic activity while an affect of CIPsMBP on mineralization was only observed at high doses. We tested this drug for 6 months in 23 pagetic patients distributed in three groups. Gr 1 (n = 5) receiving 200 mg/day showed a decrease of serum alkaline phosphatase (SAP) to 42 +/- 4% (p less than 0.01) of initial value (100%) while hydroxyprolinuria/creatinuria ratio (OH/Cr) dropped to 69 +/- 8% of baseline. In 4 patients receiving 400 mg/day, SAP improved to 48 +/- 9% of initial value (p less than 0.01) and OH/Cr to 40 +/- 3% (p less than 0.01). In the last group (n = 14) receiving 200 mg/day for 3 months, and 400 mg/day thereafter up to the 6th month SAP decreased to 53 +/- 4% and OH/Cr to 62 +/- 6% of initial value (p less than 0.01). Clinical improvement was significant from the first month of treatment. No resistance (mean decrease of SAP lower than 30%) was recorded and no radiological or clinical evidence of mineralization defect appeared. The clinical and biological tolerance was excellent throughout the study.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Collette, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Franchimont, Paul
Language :
English
Title :
Biological and Clinical Assessment of a New Bisphosphonate, (Chloro-4 Phenyl) Thiomethylene Bisphosphonate, in the Treatment of Paget's Disease of Bone
Alexandre, Meunier, Edouard, Khairi, Johnston (1981) Effects of ethane-1 hydroxy-1, 1-Diphosphonate (5 mg/kg/day dose) onquantitative bone histology in paget's disease of bone. Metabolic Bone Disease and Related Research 4:309-316.
Altman, Johnston, Khairi, Wellman, Serafini, Sanhey (1973) Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone. New Engl. J. Med. 289:1379-1384.
Bijvoet, Frijlink, Jie, Van Der Linden, Meyer, Mulder, Van Paasem, Reitsma, te Velde, de Vries, Van Der Wey (1980) APD in Paget's disease of bone: role of the mononuclear phagocyte system. Arthritis Rheum. 23:1193-1204.
Boonekamp, Lowik, Van Der Wee-Pals, Van Wijk-Van Lennep, Bijvoet (1987) Enhancement of the inhibitory action of APD on the transformation of osteoclasts precursors into resorbing cells after dimethylation of the amino group. Bone and Min. 2:29-42.
Charhon, Meunier, Etghen, Lacheretz, Breliere, Roncuccir (1985) Histomorphometric analysis of bone biopsies of baboons treated with “SR 41319 B” a new diphosphonate. Calcif. Tiss. Int. 38:833.
De Vries, Bijvoet (1974) Results of prolonged treatment of Paget's disease of bone with disodium ethane 1-hydroxy 1, 1-diphosphonate (EHDP). Neth. J. Med. 17:281-298.
Dewis, Prasad, Anderson, Willets (1985) Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. Ann. Rheum. Dis. 44:34-38.
Emonds-Alt, Breliere, Roncucci (1985) Effects of 1-hydroxyethilidene-1, 1 biphosphonate and (chloro-4 phenyl) thiomethylene biphosphonic acid (SR 41319 B) on the mononuclear cell factor-mediated release of neutral proteinoses by articular chondrocytoses and synovial cells. Biochem. Pharmacol. 34:4043-4049.
Emonds-Alt, Barbier, Breliere, Roncucci (1985) Anti-arthritic and anti-osteoporotic activities of (chloro-4 phenyl) thiomethylene biphosphonic acid (SR 41319 B) pharmacological studies. Calcif. Tiss. Int. 38:834.
Felix, Bettex, Fleisch (1981) Effect of diphosphonates on the synthesis of prostaglandines in cultured calvaria cells. Calcif. Tiss. Int. 33:549-552.
Fleisch (1987) Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin. Orthop. Rel. Res. 217:72-78.
Fleisch, Russel, Francis (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1261-1264.
Frislink, te Velde, Bijvoet, Heynen (1979) Treatment of Paget's disease of bone with (3-amino-1-hydroxypropilidene-1, 1-bisphosphonate) (APD). Lancet 1:799-803.
Gasser, Morgan, Fleisch, Richelle (1987) The influence of two diphosphonates on calcium metabolism in the rat. Clin. Sci. 43:31-45.
Harinck, Bijvoet, Blanksma, Dalinghaus-Nienhuys (1987) Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin. Orthop. Rel. Res. 217:79-98.
Harris, Neer, Segre, Petkau, Tulli, Daly, Potts (1982) Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease. J. Clin. Endocrinol. Metab. 55:100-1107.
Heynen, Reuter, Vrindts, Saussel, Cramilton, Gaspard, Franchimont Parathyroid hormone assay and its clinical applications, Institut des Radio Elements; 1979.
Heynen, Delwaide, Bijvoet, Franchimont (1982) Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone. European Journal of Clinical Investigation 11:29-33.
Hosking (1981) Calcitonin and diphosphonate in the treatment of paws disease of bone. Metabolic Bone Disease and Related Research 4:317-326.
Kanis, Gray (1987) Long term follow-up observations on treatment in Paget's disease of bone. Clin. Orthop. Rel. Res. 217:99-125.
Khairi, Altman, de Rosa, Zimmerman, Schenk, Johnston (1977) Sodium etidronate in the treatment of Paget's disease of bone. Ann. Int. Med. 87:656-663.
Mautalen, Gonzalez, Chiringelli (1985) Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone 6:429-432.
Meunier, Coindre, Edouard, Arlot (1980) Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and non-pagetic bone tissues. Arth. Rheum. 23:1095-1103.
Meunier, Chapuy, Alexandre, Bressot, Edouard, Vignon, Mathieu, Treschel (1979) Effects of disodium dichloromethylene diphosphonate (CL2 MDP) on Paget's disease of bone. Lancet 2:489.
Mills, Singer (1976) Nuclear inclusions in Paget's disease of bone. Science 194:201-202.
Nordin (1978) Diagnostic procedures in disorders of calcium metabolism. Clin. Endocrinol. 8:55-67.
Plasmans, Kuypers, Sloof (1978) The effect of EHDP on matrixinduced ectopic bone formation. Clin. Orthop. Rel. Res. 132:233-243.
Price, Nishimoto (1980) Radioimmunoassay for the vitamin-K-dependent protein of bone its discovery in plasma. Proc. Natl. Acad. Sci. USA 77:2234-2238.
Reitsma, Teitelbaum, Bijvoet (1982) Differential action of the bisphosphonates on rat macrophage mediated bone resorption in vitro. J. Clin Invest. 70:927-933.
Reitsma, Bijvoet, Van Der Wee-Pals (1980) Kinetic studies of bone and mineral metabolism during treatment with APD in rats. Calcif. Tiss. Int. 32:145-157.
Shiroda, Adamek, Felix, Fleisch, Schenk, Hagan (1987) Structure-activity relationships of various bisphosphonates. Calcif. Tiss. Int. 35:87-89.
Thiebaut, Jaeger, Burckhardt (1987) Paget's disease of bone treated in five days with AHPrBP (APD) per Os. Journal of Bone and Mineral Research 2:45-52.
Trayser, Seligson (1969) A new kinetic method for enzyme analysis suitable for automation. Clin. Chem. 15:452.
Vignery, Baron (1980) Comparative effects of APD and CL2 MDP on bone in the rat: in vivo and in vitro studies. Metab. Bone Dis. Rel. Res. 2:381-387.